Flutamide Articles

ProStrakan buys Spanish firm Elfar to expand in Spain

28 February 2005

Replace PIIP with R&D subsidiaries, says Australian Productivity Commission

24 February 2003

SPAN seeking US FTC probe of aaiPharma

10 December 2001

Generic flutamide reaches US market

20 September 2001

aaiPharma and Teva patent deal

11 September 2001

Cipla mulls felodipine deal with Mutual

10 April 2001

Opponents of Claritin bill claim Senate win

5 July 2000

US consumers and seniors campaign against drugmakers' handouts to Congress

2 November 1999

S 1172 "will add $9.64 billion to Schering-Plough's revenues during 2002-12"

10 August 1999

Proposed drug patent extensions "will cost US consumers $11 billion"

9 August 1999

Anti-S 1172 campaign underway in three states

4 August 1999

Coalition opposes patent extension bill

15 June 1999

Solid Growth Forecast For Schering Plough

24 August 1998

New Indication For Zeneca's Zoladex

29 July 1998

Schering-Plough In Singapore

19 May 1997

Forex Impacts Sales At Pfizer, Merck And S-P

22 April 1997

Schering-Plough: Facility In Mexico

10 March 1997

Zeneca Wins Legal Challenge To Casodex

20 January 1997

Schering-Plough Gets Approval For Flutamide Capsules

8 July 1996

Shire: An Emerging Firm With A Difference

20 May 1996

...While Firm Gets Fast-Track Approval For Casodex In USA

16 October 1995

As Casodex Nears US Approval, Writ Issued

25 September 1995

Schering-Plough Is "Right-Sized And Flexible"

3 July 1995

Casodex Tolerability Advantage Over Eulexin?

5 June 1995

First Launch For Zeneca's Casodex

8 May 1995

Zeneca Gets First Approval For Casodex

6 March 1995

End Of Year Encouraging For US Companies

6 February 1995

Odyne Launch In Japan

16 January 1995

CURRENCY AND CHARGES IMPACT 1993 US RESULTS

7 February 1994

NICOTINE PATCH COs SUFFER DECLINE IN US SALES

2 August 1993

US DRUGMAKERS AND "THE BLACK HOLE"

21 June 1993

MURPHY'S LAW PERVADES US DRUG STOCKS

17 May 1993

SCHERING-PLOUGH NOW "MORE EFFICIENT"

10 May 1993

ZENECA REPORTS ANTICANCER SUCCESSES

19 April 1993

TENORMIN DRAGS DOWN ZENECA AS IT DEMERGES

8 March 1993

WORLD ANTICANCER/ IMMUNOLOGY MARKET

8 February 1993

ZENECA'S PROMISING R&D PIPELINE PRESENTED

14 December 1992

GOOD GROWTH FOR US COMPANIESCONTINUES FOR US COs

3 August 1992

STRONG GROWTH AT SCHERING-PLOUGH

29 June 1992

GOOD SALES GROWTH FOR MAJOR US COS IN 1st QTR

27 April 1992

VOLUME GROWTH FOR US DRUGMAKERS

9 March 1992

Showing 1-41 of 41 articles

Go to beginningPrevious
  • 1
NextGo to end